跳至主要内容
临床试验/NCT02271854
NCT02271854已完成3 期

A Randomized, Double-blind, Placebo-controlled, Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel (DSG) 1% Applied Four Times Daily in Subjects Experiencing Acute Delayed Onset Muscle Soreness (DOMS) of the Lower Limbs

Novartis1 个研究点 分布在 1 个国家目标入组 102 人开始时间: 2014年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Novartis
入组人数
102
试验地点
1
主要终点
Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24), Derived From POW.

研究概览

简要总结

This study will assess the analgesic efficacy of DSG 1% compared to placebo in the reduction of the pain associated with DOMS

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female subjects aged 18-35 years
  • Not engaged in regular lower extremity fitness activities in the past 6 months prior to screening
  • Willing to refrain from use of ice, heat and massage during the study
  • DOMS score ≥4 Pain at Rest (PAR) and a DOMS score ≥5 Pain on Walking (POW), with moderate or severe on categorical scale

排除标准

  • Pain medication & corticosteroids prior to randomization
  • Topical analgesic or anti-inflammatory treatment over the previous month
  • Body mass index of >32 kg/m2
  • Other protocol-defined inclusion/exclusion criteria may apply

研究组 & 干预措施

Placebo

Placebo Comparator

Placebo gel applied four times daily

干预措施: Diclofenac sodium gel 1% (Drug)

diclofenac sodium gel 1%

Experimental

diclofenac sodium gel 1% applied four times daily

干预措施: Diclofenac sodium gel 1% (Drug)

diclofenac sodium gel 1%

Experimental

diclofenac sodium gel 1% applied four times daily

干预措施: Placebo (Drug)

Placebo

Placebo Comparator

Placebo gel applied four times daily

干预措施: Placebo (Drug)

结局指标

主要结局

Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24), Derived From POW.

时间窗: 24 hours

The primary efficacy outcome was the time-weighted SPID 24 (POW). Sum of pain intensity differences over 24 hours after initiating treatment (SPID 24) for the modified ITT population. SPID 24 derived from Pain on Walking (POW) scores assessed over 24 hours on a 0 (No pain) - 10 (Pain as bad as you can imagine) Numerical Rating Scale. SPID 24 was computed using the trapezoidal rule, i.e. Σ \[T(i) - T(i-1)\] x \[((PID)(i-1) + PID(i))/2\] in an obvious notation, where T(i) is nominal time and PID(i), the pain intensity difference at Time i, is the baseline pain intensity (PI) score - PI score at Time i.

次要结局

  • Sum of Pain Intensity Differences Over 48 Hours After Initiating Treatment (SPID 48), Derived From POW.(48 hours)

研究者

发起方
Novartis
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验